<a href="https://laohu8.com/S/IMAB">I-Mab</a> Announces Global Phase 2 Trial Initiation for Givastomig in Metastatic Gastric Cancers, Set for Q1 2026
I-Mab, a global biotech company, has announced an acceleration in the investment for its lead program, givastomig, an investigational bispecific antibody targeting Claudin 18.2 (CLDN18.2) for the treatment of metastatic gastric cancers. The company plans to initiate a global randomized Phase 2 study of givastomig in combination with immunochemotherapy in the first quarter of 2026. Additionally, I-Mab aims to report topline data from its Phase 1b dose expansion study, which is evaluating givastomig at two dose levels in combination with nivolumab and chemotherapy, in the first quarter of 2026. The development strategy will also be broadened to include locally advanced gastric cancer and other Claudin 18.2-positive tumor types, such as biliary tract cancer and pancreatic ductal adenocarcinoma.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. I-Mab published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-113369), on September 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.